New drug Neu2000 to be used for stroke prevention

GNT Pharma 기본형2

Stroke is when poor blood flow to the brain results in cell death. There are two main types of stroke: ischemic, due to lack of blood flow, and hemorrhagic, due to bleeding. They result in part of the brain not functioning properly. Signs and symptoms of a stroke may include an inability to move or feel on one side of the body, problems understanding or speaking, feeling like the world is spinning, or loss of vision to one side among others. Signs and symptoms often appear soon after the stroke has occurred. If symptoms last less than one or two hours, it is known as a transient ischemic attack (TIA). Hemorrhagic strokes may also be associated with a severe headache. The symptoms of a stroke can be permanent. Long term complications may include pneumonia or loss of bladder control. The main risk factor for stroke is high blood pressure. Other risk factors include tobacco smoking, obesity, high blood cholesterol, diabetes mellitus, previous TIA, and atrial fibrillation. An ischemic stroke is typically caused by blockage of a blood vessel.

GNT Pharma_대표사진(1)

A hemorrhagic stroke is caused by bleeding either directly into the brain or into the space surrounding the brain. Bleeding may occur due to a brain aneurysm. Diagnosis is typically with medical imaging such as a computerized axial tomography (CT) scan or magnetic resonance imaging (MRI) scan along with a physical exam. Other tests such as an electrocardiogram (ECG) and blood tests are done to determine risk factors and rule out other possible causes. Low blood sugar may cause similar symptoms. Prevention includes decreasing risk factors as well as possibly aspirin, statins, or surgery to open up the arteries to the brain in those with problematic narrowing, and warfarin in those with atrial fibrillation. A stroke often requires emergency care. An ischemic stroke, if detected within three to four and half hours, may be treatable with a medication that can break down the clot. Aspirin should be used. Some hemorrhagic strokes benefit from surgery.

Treatment to try recover lost function is called stroke rehabilitation and ideally takes place in a stroke unit; however, these are not available in much of the world. In 2013, approximately 6.9 million people had an ischemic stroke and 3.4 million people had a hemorrhagic stroke. In 2010, there were about 33 million people who had previously had a stroke and were still alive. The first fact of the affirmative must explain in clear terms what they believe the topic means. In the United States, the only currently FDA-approved treatment for stroke is thrombolytic therapy using recombinant human tissue plasminogen activator (TPA). However, TPA is given to only about 3–5% of stroke patients due to its narrow therapeutic time window of 3.5–4.5 h and its potentially toxic side effects, which include an increased risk of hemorrhagic conversion.

GNT Pharma_대표사진(2)

Hemorrhagic conversion is characterized by increased bleeding into the brain leading to further neuronal loss, inflammation, and increased cerebral edema. A recent clinical study has shown that the time window for TPA administration cannot be safely extended without loss of effectiveness (Saver et al., 2013). However, overcoming these issues requires a new approach to new treatment (medicine), as so it would like to introduce a new pharmaceutical research and development company. GNT Pharma went through clinical trials and has shown a new drug (Neu2000) to be effective in slowing the rate of infection and superior effects on stroke. The new drug has gotten many attention of pharmaceutical companies and showing effective results.

  • GNT Pharma Co.,Ltd
  • CEO : Byoung-Joo Gwag
  • Email : [email protected]
  • T : + 8231-8005-9910
  • http://gntpharma.com/en/home_en/